Today: 20 May 2026
Browse Category

NASDAQ:XCUR 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.
9 December 2025
··········
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure shares surged over 100% in pre-market trading December 9 after reporting positive topline Phase 2 results for burixafor in multiple myeloma at the ASH meeting. The trial met its primary endpoint in 17 of 19 patients, with no serious drug-related adverse events. XCUR closed at $5.33 on December 8, up 8.78%, and traded as high as $10.84 pre-market, pushing market cap to around $30–40 million.
9 December 2025
··

Stock Market Today

  • UiPath Shares Dip Amid Microsoft Korea Collaboration and Cloud Automation Expansion
    May 19, 2026, 7:30 PM EDT. UiPath (PATH) shares fell 0.99% to $10.54 on heightened trading volume following a collaboration with Microsoft Korea to launch Automation Cloud locally, aiming to boost regional cloud automation adoption. The initiative offers Korean enterprises local data residency support, crucial for managing sensitive workflows, and aligns with UiPath's shift toward partner-driven cloud sales. Broader market movements saw the S&P 500 drop 0.67% and the Nasdaq Composite decline 0.84%, with key enterprise software peers Microsoft and ServiceNow also closing lower. Investors are watching to see if local deployments in South Korea translate into consistent cloud revenue growth for UiPath.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
Go toTop